226 related articles for article (PubMed ID: 31954773)
21. Ketamine: A Paradigm Shift for Depression Research and Treatment.
Krystal JH; Abdallah CG; Sanacora G; Charney DS; Duman RS
Neuron; 2019 Mar; 101(5):774-778. PubMed ID: 30844397
[TBL] [Abstract][Full Text] [Related]
22. Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine.
Dong C; Zhang JC; Yao W; Ren Q; Ma M; Yang C; Chaki S; Hashimoto K
Int J Neuropsychopharmacol; 2017 Mar; 20(3):228-236. PubMed ID: 27765808
[TBL] [Abstract][Full Text] [Related]
23. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression.
Koike H; Fukumoto K; Iijima M; Chaki S
Behav Brain Res; 2013 Feb; 238():48-52. PubMed ID: 23098797
[TBL] [Abstract][Full Text] [Related]
24. Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats.
Podkowa K; Pochwat B; Brański P; Pilc A; Pałucha-Poniewiera A
Psychopharmacology (Berl); 2016 Aug; 233(15-16):2901-14. PubMed ID: 27286960
[TBL] [Abstract][Full Text] [Related]
25. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
Dogra S; Conn PJ
Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
[TBL] [Abstract][Full Text] [Related]
26. mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice.
Gleason SD; Li X; Smith IA; Ephlin JD; Wang XS; Heinz BA; Carter JH; Baez M; Yu J; Bender DM; Witkin JM
CNS Neurol Disord Drug Targets; 2013 Aug; 12(5):554-66. PubMed ID: 23574174
[TBL] [Abstract][Full Text] [Related]
27. An update on NMDA antagonists in depression.
Pochwat B; Nowak G; Szewczyk B
Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
[No Abstract] [Full Text] [Related]
28. Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms.
Kato T; Duman RS
Pharmacol Biochem Behav; 2020 Jan; 188():172827. PubMed ID: 31733218
[TBL] [Abstract][Full Text] [Related]
29. The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.
Fukumoto K; Iijima M; Chaki S
Neuropsychopharmacology; 2016 Mar; 41(4):1046-56. PubMed ID: 26245499
[TBL] [Abstract][Full Text] [Related]
30. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
Chappell MD; Li R; Smith SC; Dressman BA; Tromiczak EG; Tripp AE; Blanco MJ; Vetman T; Quimby SJ; Matt J; Britton TC; Fivush AM; Schkeryantz JM; Mayhugh D; Erickson JA; Bures MG; Jaramillo C; Carpintero M; Diego JE; Barberis M; Garcia-Cerrada S; Soriano JF; Antonysamy S; Atwell S; MacEwan I; Condon B; Sougias C; Wang J; Zhang A; Conners K; Groshong C; Wasserman SR; Koss JW; Witkin JM; Li X; Overshiner C; Wafford KA; Seidel W; Wang XS; Heinz BA; Swanson S; Catlow JT; Bedwell DW; Monn JA; Mitch CH; Ornstein PL
J Med Chem; 2016 Dec; 59(24):10974-10993. PubMed ID: 28002967
[TBL] [Abstract][Full Text] [Related]
31. Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.
Pałucha-Poniewiera A; Podkowa K; Pilc A
Behav Pharmacol; 2019 Sep; 30(6):471-477. PubMed ID: 30724804
[TBL] [Abstract][Full Text] [Related]
32. Ketamine and the potential role for rapid-acting antidepressant medications.
Krystal JH
Swiss Med Wkly; 2007 Apr; 137(15-16):215-6. PubMed ID: 17525875
[No Abstract] [Full Text] [Related]
33. Glutamate-Based Drug Discovery for Novel Antidepressants.
Pałucha-Poniewiera A; Pilc A
Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
[TBL] [Abstract][Full Text] [Related]
34. mGlu receptors as potential targets for novel antidepressants.
Chaki S; Fukumoto K
Curr Opin Pharmacol; 2018 Feb; 38():24-30. PubMed ID: 29486373
[TBL] [Abstract][Full Text] [Related]
35. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM
Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973
[TBL] [Abstract][Full Text] [Related]
36. [Ketamine--a new treatment option for therapy-resistant depression].
Köhler S; Betzler F
Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
[TBL] [Abstract][Full Text] [Related]
37. mGlu
Joffe ME; Santiago CI; Oliver KH; Maksymetz J; Harris NA; Engers JL; Lindsley CW; Winder DG; Conn PJ
Neuron; 2020 Jan; 105(1):46-59.e3. PubMed ID: 31735403
[TBL] [Abstract][Full Text] [Related]
38. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
39. 5-HT
Fukumoto K; Iijima M; Funakoshi T; Chaki S
Neuropharmacology; 2018 Jul; 137():96-103. PubMed ID: 29738849
[TBL] [Abstract][Full Text] [Related]
40. Rapid antidepressant effects: moving right along.
Martinowich K; Jimenez DV; Zarate CA; Manji HK
Mol Psychiatry; 2013 Aug; 18(8):856-63. PubMed ID: 23689537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
